Kornimate/medical-research-clean huggingface dataset:
mrglitt for tle: a probe trial

Conditions: Temporal Lobe Epilepsy (TLE)

Summary: how does magnetic resonance-guided laser interstitial thermal therapy (mrglitt) impact clinical prognosis in temporal lobe epilepsy (tle)?

1. compare the clinical prognosis between magnetic resonance-guided laser interstitial thermal therapy (mrglitt) and traditional open surgery (os) on patients with temporal lobe epilepsy (tle). 2. explore the factors associated with seizure outcomes.

Eligibility criteria:
inclusion criteria: * drug-resistant epilepsy. * temporal lobe epilepsy. * participants approved. exclusion criteria: * individuals with significant medical comorbidities or conditions that pose an excessive risk for surgery, such as severe cardiovascular disease, respiratory disorders, or uncontrolled systemic infections. * brain surgery history.

Keywords: magnetic resonance-guided laser interstitial thermal therapy open surgery temporal lobe epilepsy
clinical study on fecal microbiota transplantation for diarrhea after total pancreatectomy

Conditions: Pancreatic Cancer, Resected; Diarrhea

Summary: by 2030, pancreatic cancer is projected to become the second leading cause of cancer-related deaths, with a 5-year survival rate below 10%. approximately 20% of patients are diagnosed at a borderline resectable or resectable stage, and surgical resection remains the only curative option. however, total pancreatectomy (tp) often leads to severe diarrhea (incidence rate: 43.5%) due to exocrine insufficiency, and current pancreatic enzyme replacement therapy shows limited efficacy in some patients. recent studies highlight the critical role of gut microbiota in pancreatic cancer progression and postoperative recovery. patients with pancreatic ductal adenocarcinoma (pdac) exhibit a 1000-fold increase in intrapancreatic bacterial load compared to normal tissues, with significantly elevated bacteroides abundance and reduced firmicutes and proteobacteria in fecal samples. postoperative dysbiosis is linked to complications; for example, diarrhea after cholecystectomy is dominated by proteobacteria, suggesting that microbial imbalance may underlie diarrhea following tp. to address this, the study proposes fecal microbiota transplantation (fmt) via oral capsules. fmt has proven effective in treating recurrent clostridium difficile infection by restoring healthy microbiota. this research will systematically evaluate the efficacy and safety of fmt in alleviating post-tp diarrhea through clinical indicators and 16s rdna sequencing, offering novel insights into postoperative management of pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years, regardless of gender. 2. anticipated survival ≥3 months. 3. severe post-total pancreatectomy diarrhea (as per hart score). 4. willing and able to provide written informed consent and complete follow-up assessments. 5. eastern cooperative oncology group (ecog) performance status score of 1-3. 6. no use of oral/intravenous broad-spectrum antibiotics within 3 days prior to enrollment. 7. ability to swallow capsules intact without chewing. 8. adequate organ function confirmed by screening-phase laboratory tests. exclusion criteria: 1. major organ insufficiency/failure, including but not limited to: cardiac insufficiency or heart failure renal insufficiency or renal failure hepatic insufficiency or liver failure 2. uncontrolled or severe infections. 3. documented history of: psychoactive drug abuse alcoholism illicit drug use 4. severe infections complicated by sepsis or septicemia. 5. history of severe allergic reactions or known hypersensitivity to components of liquid live-bacterial enteric-coated capsules. 6. pregnancy or lactation, or women of childbearing potential refusing contraceptive measures during the 15-week observation period. 7. gastrointestinal perforation and/or fistulas. 8. other conditions deemed ineligible by the investigator.
feasibility of an interval exercise and nutrition intervention to reduce cardiovascular disease risk factors

Conditions: Pre-Diabetic; Overweight; Obesity

Summary: purpose : test the feasibility (acceptability, adherence) of a home-based interval exercise training (iet) and nutrition program, as well as its preliminary effects on resting heart rate, blood pressure, fasting glucose, hdl, cholesterol, weight and percent body fat, among primary care patients who have at least one risk factor for cardiovascular disease (cvd). participants : 30 patients who receive care from the university of north carolina (unc) family medicine center (fmc) and meet the inclusion criteria defined below (i.e. general fmc patients, not diagnosed with severe illness), will be enrolled to test the feasibility of the home-based interval exercise and nutrition program. procedures (methods): a home-based iet and nutrition program will be piloted in 2 phases. in phase i, 15 patients will be enrolled into the program, which will take approximately 3 months. at baseline, data will be collected on age, height, weight, resting heart rate, blood pressure, fasting glucose, hemoglobin a1c, fasting lipids, cholesterol, insulin, percent body fat, cardiovascular fitness, and use a series of questionnaires to evaluate mood, sleep, hunger, and quality of life. at closeout, the investigators will measure patients' adherence to each component of the intervention. in phase ii, an additional 15 new patients will be enrolled in either the identical protocol, or a slightly modified intervention (if necessary based upon our results from phase i). all patients will have the same variables measured at baseline during their study visit at 3, 6 and 12 months after enrollment into the study.


Eligibility criteria:
inclusion criteria: patients are: 1. \> 18-85 years; 2. receive primary care in the fmc (\> 1 visit during the previous year); and 3. have ≥1 risk factor or developing risk factors for cvd (blood pressure \>130/85 mmhg, bmi \>25 kg/m2(or \~20 lbs overweight), fasting glucose \>110 mg/dl, or 4) hdl \<30) (all identified via medical record) exclusion criteria: 1. those for whom exercise and/or diet are contraindicated (e.g., scheduled for arthroplasty) or who are at risk of death in the next year (e.g., class iv heart failure, end-stage renal disease). 2. those taking medication for diabetes, blood pressure, and lipids for more than 2 years. 3. pregnant or planning on becoming pregnant within the next year. 4. allergic to any ingredient in the nutritional meal replacement.

Keywords: feasibility studies intervention pre-hypertensive pre-hyperlipidemia
functional movement analysis (fms) of diaphragmatic breathing-immediate effect on shoulder mobility

Conditions: Shoulder Pain; Diaphragm Issues

Summary: the diaphragm is defined as a thin, smooth muscle that separates the thoracic and abdominal cavities. the shoulder and diaphragm muscle have a clear relationship through innervation and myofascial tissue connection. fascia is often neglected medically, rehabilitatively, or performance as the underlying cause of problems. bones, organs, and muscles appear to float in the fascial web, a continuous three-dimensional system of connective tissue. plastic and viscoelastic properties, which can change tension and shape under the influence of manual techniques and movement retraining, ensure that the structural changes are reversible. functional movement analysis (fms) is a screening system that aims to predict the risk of injury and functional deficiencies. fms consists of 7 basic motion component tests. it is scored on a scale of zero to three and creates a composite score whose sum ranges from 0 to 21 points. one of the 7 motion models evaluated is shoulder mobility. according to the results of this study, people who perform activities that require shoulder mobility will be guided as to whether the use of diaphragmatic breathing will be effective for preparation, rehabilitation or performance improvement. the aim of the study was to observe whether shoulder mobility increased in healthy individuals taught diaphragm breathing compared to the control group.


Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * individuals between the ages of 18-30 exclusion criteria: * have a musculoskeletal injury/operation involving the shoulder area in the last 6 months * using drugs that can affect the respiratory system * have received aerobic exercise training in the last 6 weeks

Keywords: diaphragmatic breathing functional movement analysis (fms) shoulder mobility
efficacy and tolerability of lidocaine plaster for treatment of long-term local nerve pain

Conditions: Pain; Chronic Pain; Neuropathic Pain; Postoperative Pain

Summary: the purpose of this trial is to investigate the efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain in comparison to placebo plaster.


Eligibility criteria:
inclusion criteria: * male or female subjects aged 18 years or older. * subjects suffering from moderate to severe localized chronic ponp (post operative neuropathic pain) pain following surgery (e.g., thoracotomy, total/partial knee replacement, cholecystectomy, mastectomy, inguinal hernia repair, varicose vein stripping). * localized ponp present for at least 3 months. * size of the affected painful skin area is not larger than the size of 3 plasters. * intact skin besides the scar of surgery in the area of plasters application * baseline average pain intensity of 4 or greater on the 11 point pain intensity numeric rating scale. exclusion criteria: * participation in another trial (with medicine or a device under investigation) in parallel or less than 30 days prior to enrollment in this trial. * previous enrollment in this trial. * history of dependency or active drug abuse (alcohol, medication) during the 1 year prior to enrollment. * evidence or history (during the 3 years prior to enrollment) of neurotic personality or psychiatric illness that in the investigator's opinion may affect efficacy or safety assessments or may compromise the subjects safety during trial participation. * pregnant or breastfeeding women or women of childbearing potential who are sexually active without satisfactory contraception. * any surgery performed in the 3 months prior to enrollment, which may affect efficacy or safety assessment. * any surgery scheduled or expected during the trial. * clinically significant disease (e.g., acquired immunodeficiency syndrome) or condition that may affect efficacy or safety assessments, or any other reason which, in investigator's opinion, may preclude the subject's participation in the trial. * history of malignancy (with the exception of neoplasia related to the trial indication) within 2 years prior to enrollment. * subject with ponp related to a surgery due to neoplasia: suspected residual neoplasia or metastases. * pending litigation due to chronic pain or disability. * total anesthesia in the cutaneous area neurologically related to the location of the surgical intervention. * hypersensitivity to the lidocaine 5% medicated plaster, its excipients, or anesthetics of the amide type. * any former use of topical lidocaine in the area of localized chronic ponp. * severe renal, hepatic or heart disorder.
adjuvant intravitreal bevacizumab in pars plana vitrectomy for diabetic vitreous hemorrhage

Conditions: Recurrent; Hemorrhage

Summary: postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative diabetic retinopathy. there have been efforts to lower the incidence of postoperative vitreous hemorrhage such as preoperative bevacizumab injection. bevacizumab (avastin) is a potent inhibitor of angiogenesis and has been shown to decrease retinal and iris neovascularization in proliferative diabetic retinopathy. recently there have been reports showing that preoperative bevacizumab injection could reduce intraoperative bleeding from abnormal vessels and could make surgery easier and more successful. our hypothesis is that intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by inhibiting the vessel formation after surgery. we started the prospective randomized comparative study to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without any adjuvant drug.


Eligibility criteria:
inclusion criteria: * patients undergoing first vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy exclusion criteria: * follow-up period of less than 3 months * not first vitrectomy * abnormal blood coagulation * uncontrolled hypertension
randomized trial of image -guided stereotactic radiation therapy (ig-srt) in prostate cancer

Conditions: Prostate Cancer

Summary: patients with low-risk or favorable intermediate-risk prostate cancer as defined by 1.2016 nccn criteria will be eligible to participate on this study.

this is a randomized, two arm study for patients with low-risk or favorable intermediate-risk prostate cancer as defined by 1.2016 nccn criteria. patients will be randomized to either rectal spacer placement or endorectal balloon placement, daily prior to each radiation treatment. 1. endorectal balloon (erb): immobilization device manually placed into the rectum prior to radiation treatment planning ct and daily treatment delivery, to immobilize the prostate and reduce prostate motion. 2. rectal spacer (rs): biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. the spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months. this study plans to enroll a total of 40 patients with an accrual period of 4 years.

Eligibility criteria:
inclusion criteria: * biopsy-proven diagnosis of prostate adenocarcinoma, diagnosed within 1 year of randomization * either nccn-defined low-risk disease (t1c-t2a, gleason score 3+3=6, psa \ 20 ng/ml, but not due to t3-t4 disease on physical exam. exclusion criteria: * history of prior pelvic radiation (external beam or brachytherapy) * prior or concurrent lymphomatous/hematogenous malignancy, or history of prior/concurrent invasive malignancy during the past 5 years * very high risk prostate cancer (t3b-t4 on clinical exam, primary gleason pattern 5, or \>4 cores with gleason score 8-10) * history of prior chemotherapy for prostate cancer * history of irritable bowel disease * evidence of lymph node involvement * aua score \>15 * prostate size \> 90 cc
oasis: peer support for t2dm in appalachia (peer participant)

Conditions: Diabetes Mellitus, Type 2

Summary: the goal of this clinical trial is to compare the effects of peer coaching models in older adults with unmanaged type two diabetes. the main questions it aims to answer are: are peer coaching models effective at promoting type 2 diabetes mellitus self-management? if effective, which facets of the peer model are most effective? peer coaches will undergo peer coach training. reach out to peer participants on a weekly/biweekly time frame to discuss self-management and goal setting. retain records of contact, topics discussed, and general notes on interactions. researchers will compare differences in the frequency of contact, as well as how peer coaches were matched to peer participants to see if efficacy of the intervention is altered between groups.

the older adults using social support to improve self-care (oasis) intervention is an asset-based approach, utilizing the unique social structure existing in kentucky's rural appalachian communities to address self-care behaviors as they relate to type 2 diabetes mellitus (t2dm) management. the intervention will be composed of two groups: peer coaches who have managed t2dm (hba1c \ 7.5%). peer coaches will undergo training prior to intervention initiation to develop coaching skills. peer participants will be linked to a peer coach in one of four ways: (1) self-select coach with contact once a week (2) self-selected coach with contact every 2 weeks (3) matched with peer coach with contact once a week (4) matched with peer coach with contact every 2 weeks. in addition to evaluating the effectiveness of a peer coaching model, the four groups will be evaluated allowing for a more detailed understanding of factors that influence self-care behaviors. stakeholders will also be engaged at three time points: prior to the intervention, study mid-point, and at study conclusion. at study conclusion, a small cohort of both peer participants and peer coaches will be invited to contribute to stakeholder group interviews. information exchange with stakeholders will aid in developing a robust understanding of influential factors and how to effectively promulgate the intervention.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 55 years * resident in rural kentucky * positive diagnosis of type 2 diabetes mellitus * hba1c greater than or equal to 7.5% * passing score on cognitive assessment administered by study personnel * english speaking exclusion criteria: * age less than 55 years * not a resident of a rural kentucky county * no type 2 diabetes mellitus diagnosis * hba1c under 7.5% * cognitive impairment * non-english speaking

Keywords: appalachian region peer influence diabetes mellitus, type 2
fever of unknown orgin registry in internal medicine unit and infectious disease units

Conditions: Fever of Unknown Origin

Summary: this registry has the aim to collect epidemiological and clinical data of classical fuo cases in italian internal medicine dept. and in italian infection diseases dept.

in particular this registry intends to record clinical data observed, diagnostic methods used and the clinical evolution of classical fuo cases

Eligibility criteria:
inclusion criteria: * • fever (temperature \> 38.3° c) found in several occasions of a duration exceeding 3, unable to make a diagnosis after a period of 3 days of hospitalization or after 3 out-patients visits in internal medicine dept. or infection diseases dept. * signed informed consent exclusion criteria: * • immunocompromised patients * patients in treatment with steroidi (prednisone \> 0,5 mg/kg/die per \> 4 weeks), anti-tnf, ciclofosfamide, tacrolimus, everolimus, sirolimus, azatioprina, ciclosporina, micofenolato, metotrexate * neutropenic patients with less than 500 neutrofili/µl * hiv positive patients * nocosomial fever.
turkish validity and reliability of gait outcomes assessment list (goal)

Conditions: Cerebral Palsy

Summary: the aim of this study is to investigate the reliability and validity of the turkish gait outcomes assessment list (goal) questionnaire, in children with cerebral palsy (cp) with gmfcs level1, 2, and 3.

most children with cerebral palsy (cp) can walk. musculoskeletal disorders of these children cause deterioration in gait functions. disruptions in gait limit children's participation. to minimize these impairments, various interventions are usually applied to children with cp who can walk. the ultimate goal of these interventions is to help these children achieve the best possible participation in activities of daily living. in addition, goal determination by children and families in treatment planning is important in terms of treatment success. the gait outcomes assessment list (goal) is a scale developed to contribute to the determination of these goals. this questionnaire includes the priorities, expectations, and goals of children with cp who can walk and reveals their walking characteristics. the questionnaire is used in two languages, english and german, and there is no turkish version of the questionnaire. therefore, the aim of this study is to create the turkish version of the 'gait outcomes assessment list (goal)' family and child questionnaires and to examine its validity and reliability.

Eligibility criteria:
inclusion criteria: * diagnosed with cerebral palsy * being able to read and write turkish exclusion criteria: * children who have had botox or orthopedic surgery in the last 6 months
molecular and diagnostic classification of non-small cell lung cancer from fine needle aspirates

Conditions: Non-Small Cell Lung Cancer

Summary: the goal of this study is to demonstrate the feasibility of using a novel, validated panel of non-small cell lung cancer (nsclc) histology-predictive genes (the "a/s signature) as a diagnostic tool for use with small-volume fine needle aspirate (fna) biopsies. objectives: 1. to establish fna biopsy requirements for fna-based subtype classification of nsclc. 2. to define a "fixed statistical model" of histologic subtype prediction in nsclc. study methods: to establish fna biopsy requirements for gene expression-based subtype classification of nsclc, patients with presumed newly diagnosed nsclc, where radiographic studies and clinical description favor a probable diagnosis of nsclc, will undergo fna biopsy according to current standard techniques . for this part of the study, approximately 40 biopsies of confirmed nsclc will be collected for analysis. to define a fixed statistical model of histologic subtype prediction in nsclc, we will prospectively collect 50 fnas. these fnas will represent adenocarcinoma (ac) and squamous cell carcinoma (scc) cases at a ratio of approximately 1:1. additional cases of not otherwise specified (nos), should they be encountered, may also be collected for later analysis. fna samples qualified based on cell number or ribonucleic acid (rna) yield (depending on the findings of our primary objective)will be assayed on the qgs platform.


Eligibility criteria:
inclusion criteria: * patients undergoing a diagnostic fna by the following diagnostic modalities utilizing fna: trans-thoracic needle biopsy (tnb), endobronchial ultrasound guided transbronchial needle aspiration (ebus-tbna), trans-esophageal ultrasound scanning with fna (eus-fna). * patients must have radiographic evidence for presumed lung cancer or have a previously diagnosed nsclc with potential recurrence. patient undergoing fna of potential nsclc metastatic lesions are also included (e.g., patients with hepatic metastases). * age \>18 years. used to define adult age who can independently provide consent. * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * patients whose fna biopsy is unable to provide subtype classification by pathology or is non-diagnostic.

Keywords: trans-thoracic needle biopsy (tnb) endobronchial ultrasound guided transbronchial needle aspiration (ebus-tbna) trans-esophageal ultrasound scanning with fna (eus-fna)
telemonitoring of cpap therapy in sleep apnea patients

Conditions: Obstructive Sleep Apnea

Summary: wireless telemonitoring is compared with regular nursing procedure in terms of patient satisfaction, adherence to continuous positive pressure (cpap) treatment and nursing time during the habituation phase of the cpap therapy in obstructive sleep apnea syndrome (osas).

both patients and study nurses were unblinded for the wireless telemonitoring system (restraxx™online, resmed, sydney, australia). the module was attached to the s9 elite™ (resmed, sydney, australia) cpap device, which transmitted compliance data every day automatically to the restraxx™ online (resmed, sydney, australia) data base. the treatment was considered successful when cpap use was \>4 h/day, mask leak \<0.4 l/s, and ahi \<5/h during the last 6 days. study nurses made the data check-ups daily during weekdays and if the criteria for successful cpap therapy was not achieved during two consecutive nights the nurses adjusted the cpap pressure remotely and called the patient to give further advice. patients had also a control viist aftr one year.

Eligibility criteria:
inclusion criteria: * adult patients with diagnosed obstructive sleep apnea exclusion criteria: * not able to understand finnish language * unable to co-operate

Keywords: sleep apnea cpap treatment telemedicine nursing time patient satisfaction